🇺🇸 FDA
Patent

US 10993936

Method of treating one or more symptoms of pulmonary fibrosis by administering inhibitors of nicotinamide phosphoribotransferase

granted A61KA61K31/4439A61K31/444

Quick answer

US patent 10993936 (Method of treating one or more symptoms of pulmonary fibrosis by administering inhibitors of nicotinamide phosphoribotransferase) held by Arizona Board of Regents on Behalf of the University of Arizona expires Mon Apr 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Arizona Board of Regents on Behalf of the University of Arizona
Grant date
Tue May 04 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
23
CPC classes
A61K, A61K31/4439, A61K31/444, A61K31/4545, A61K31/713